APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anthrax Vaccines

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Selected research

Market Analysis & Forecast

Global Anthrax Vaccines Market Analysis and Forecast 2026-2032

1 January 2026212 pages

Choose your research edition.

Industry ResearchAnthrax Vaccines Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Anthrax Vaccines Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Anthrax Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anthrax Vaccines Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Anthrax Vaccines Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Global Anthrax Vaccines key players include Emergent BioSolutions, Merial, Merck, Zoetis, PharmAthene, etc. Global top five players hold a share about 70%.

North America is the largest market, with a share about 60%, followed by Latin America and Europe, having a total share about 20 percent.

Read the full market overview

In terms of product, Live Vaccines is the largest segment, with a share about 95%. And in terms of application, the largest application is Human Use, followed by Animal Use.

This report presents an overview of global market for Anthrax Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anthrax Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Anthrax Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anthrax Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anthrax Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Anthrax Vaccines sales, projected growth trends, production technology, application and end-user industry.

Anthrax Vaccines Segment by Company

Emergent BioSolutions

Merial

Merck

Zoetis

Bayer Sanidad Animal

Colorado Serum

PharmAthene

Tiankang

Biogénesis-Bago

CAVAC

Rosenbusch

Agrovet

Vecol

CVCRI

IVPM

Prondil

CDV

Indian Immunologicals

Botswana Vaccine Institute

Ceva Santé Animale

Intervac

JOVAC

Anthrax Vaccines Segment by Type

Live Vaccines

Cell free PA Vaccines

Anthrax Vaccines Segment by Application

Human Use

Animal Use

Anthrax Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anthrax Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anthrax Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anthrax Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Anthrax Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Anthrax Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anthrax Vaccines sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anthrax Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Live Vaccines Major Manufacturers Table 3. Cell free PA Vaccines Major Manufacturers Table 4. Global Anthrax Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Human Use Major Manufacturers Table 6. Animal Use Major Manufacturers Table 7. Anthrax Vaccines Industry Trends Table 8. Anthrax Vaccines Industry Drivers Table 9. Anthrax Vaccines Industry Opportunities and Challenges Table 10. Anthrax Vaccines Industry Restraints Table 11. Global Anthrax Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Anthrax Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Anthrax Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Anthrax Vaccines Revenue Market Share by Region (2021-2026) Table 15. Global Anthrax Vaccines Revenue Market Share by Region (2027-2032) Table 16. Global Anthrax Vaccines Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (M Doses) Table 17. Global Anthrax Vaccines Sales by Region (2021-2026) & (M Doses) Table 18. Global Anthrax Vaccines Sales by Region (2027-2032) & (M Doses) Table 19. Global Anthrax Vaccines Sales Market Share by Region (2021-2026) Table 20. Global Anthrax Vaccines Sales Market Share by Region (2027-2032) Table 21. Global Anthrax Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Anthrax Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Anthrax Vaccines Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Anthrax Vaccines Sales Market Share by Manufacturers (2021-2026) Table 25. Global Anthrax Vaccines Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 26. Global Anthrax Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Anthrax Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Anthrax Vaccines Manufacturers, Product Type & Application Table 29. Global Anthrax Vaccines Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Anthrax Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Anthrax Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Anthrax Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Anthrax Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Anthrax Vaccines Revenue Market Share by Type (2021-2026) Table 36. Global Anthrax Vaccines Revenue Market Share by Type (2027-2032) Table 37. Global Anthrax Vaccines Sales by Type 2021 VS 2025 VS 2032 (M Doses) Table 38. Global Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 39. Global Anthrax Vaccines Sales by Type (2027-2032) & (M Doses) Table 40. Global Anthrax Vaccines Sales Market Share by Type (2021-2026) Table 41. Global Anthrax Vaccines Sales Market Share by Type (2027-2032) Table 42. Global Anthrax Vaccines Price by Type (2021-2026) & (USD/Dose) Table 43. Global Anthrax Vaccines Price by Type (2027-2032) & (USD/Dose) Table 44. Global Anthrax Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Anthrax Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Anthrax Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Anthrax Vaccines Revenue Market Share by Application (2021-2026) Table 48. Global Anthrax Vaccines Revenue Market Share by Application (2027-2032) Table 49. Global Anthrax Vaccines Sales by Application 2021 VS 2025 VS 2032 (M Doses) Table 50. Global Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 51. Global Anthrax Vaccines Sales by Application (2027-2032) & (M Doses) Table 52. Global Anthrax Vaccines Sales Market Share by Application (2021-2026) Table 53. Global Anthrax Vaccines Sales Market Share by Application (2027-2032) Table 54. Global Anthrax Vaccines Price by Application (2021-2026) & (USD/Dose) Table 55. Global Anthrax Vaccines Price by Application (2027-2032) & (USD/Dose) Table 56. Emergent BioSolutions Company Information Table 57. Emergent BioSolutions Business Overview Table 58. Emergent BioSolutions Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 59. Emergent BioSolutions Anthrax Vaccines Product Portfolio Table 60. Emergent BioSolutions Recent Development Table 61. Merial Company Information Table 62. Merial Business Overview Table 63. Merial Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 64. Merial Anthrax Vaccines Product Portfolio Table 65. Merial Recent Development Table 66. Merck Company Information Table 67. Merck Business Overview Table 68. Merck Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 69. Merck Anthrax Vaccines Product Portfolio Table 70. Merck Recent Development Table 71. Zoetis Company Information Table 72. Zoetis Business Overview Table 73. Zoetis Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 74. Zoetis Anthrax Vaccines Product Portfolio Table 75. Zoetis Recent Development Table 76. Bayer Sanidad Animal Company Information Table 77. Bayer Sanidad Animal Business Overview Table 78. Bayer Sanidad Animal Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 79. Bayer Sanidad Animal Anthrax Vaccines Product Portfolio Table 80. Bayer Sanidad Animal Recent Development Table 81. Colorado Serum Company Information Table 82. Colorado Serum Business Overview Table 83. Colorado Serum Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 84. Colorado Serum Anthrax Vaccines Product Portfolio Table 85. Colorado Serum Recent Development Table 86. PharmAthene Company Information Table 87. PharmAthene Business Overview Table 88. PharmAthene Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 89. PharmAthene Anthrax Vaccines Product Portfolio Table 90. PharmAthene Recent Development Table 91. Tiankang Company Information Table 92. Tiankang Business Overview Table 93. Tiankang Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 94. Tiankang Anthrax Vaccines Product Portfolio Table 95. Tiankang Recent Development Table 96. Biogénesis-Bago Company Information Table 97. Biogénesis-Bago Business Overview Table 98. Biogénesis-Bago Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 99. Biogénesis-Bago Anthrax Vaccines Product Portfolio Table 100. Biogénesis-Bago Recent Development Table 101. CAVAC Company Information Table 102. CAVAC Business Overview Table 103. CAVAC Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 104. CAVAC Anthrax Vaccines Product Portfolio Table 105. CAVAC Recent Development Table 106. Rosenbusch Company Information Table 107. Rosenbusch Business Overview Table 108. Rosenbusch Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 109. Rosenbusch Anthrax Vaccines Product Portfolio Table 110. Rosenbusch Recent Development Table 111. Agrovet Company Information Table 112. Agrovet Business Overview Table 113. Agrovet Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 114. Agrovet Anthrax Vaccines Product Portfolio Table 115. Agrovet Recent Development Table 116. Vecol Company Information Table 117. Vecol Business Overview Table 118. Vecol Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 119. Vecol Anthrax Vaccines Product Portfolio Table 120. Vecol Recent Development Table 121. CVCRI Company Information Table 122. CVCRI Business Overview Table 123. CVCRI Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 124. CVCRI Anthrax Vaccines Product Portfolio Table 125. CVCRI Recent Development Table 126. IVPM Company Information Table 127. IVPM Business Overview Table 128. IVPM Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 129. IVPM Anthrax Vaccines Product Portfolio Table 130. IVPM Recent Development Table 131. Prondil Company Information Table 132. Prondil Business Overview Table 133. Prondil Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 134. Prondil Anthrax Vaccines Product Portfolio Table 135. Prondil Recent Development Table 136. CDV Company Information Table 137. CDV Business Overview Table 138. CDV Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 139. CDV Anthrax Vaccines Product Portfolio Table 140. CDV Recent Development Table 141. Indian Immunologicals Company Information Table 142. Indian Immunologicals Business Overview Table 143. Indian Immunologicals Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 144. Indian Immunologicals Anthrax Vaccines Product Portfolio Table 145. Indian Immunologicals Recent Development Table 146. Botswana Vaccine Institute Company Information Table 147. Botswana Vaccine Institute Business Overview Table 148. Botswana Vaccine Institute Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 149. Botswana Vaccine Institute Anthrax Vaccines Product Portfolio Table 150. Botswana Vaccine Institute Recent Development Table 151. Ceva Santé Animale Company Information Table 152. Ceva Santé Animale Business Overview Table 153. Ceva Santé Animale Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 154. Ceva Santé Animale Anthrax Vaccines Product Portfolio Table 155. Ceva Santé Animale Recent Development Table 156. Intervac Company Information Table 157. Intervac Business Overview Table 158. Intervac Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 159. Intervac Anthrax Vaccines Product Portfolio Table 160. Intervac Recent Development Table 161. JOVAC Company Information Table 162. JOVAC Business Overview Table 163. JOVAC Anthrax Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 164. JOVAC Anthrax Vaccines Product Portfolio Table 165. JOVAC Recent Development Table 166. North America Anthrax Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 167. North America Anthrax Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 168. North America Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 169. North America Anthrax Vaccines Sales by Type (2027-2032) & (M Doses) Table 170. North America Anthrax Vaccines Sales Price by Type (2021-2026) & (USD/Dose) Table 171. North America Anthrax Vaccines Sales Price by Type (2027-2032) & (USD/Dose) Table 172. North America Anthrax Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 173. North America Anthrax Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 174. North America Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 175. North America Anthrax Vaccines Sales by Application (2027-2032) & (M Doses) Table 176. North America Anthrax Vaccines Sales Price by Application (2021-2026) & (USD/Dose) Table 177. North America Anthrax Vaccines Sales Price by Application (2027-2032) & (USD/Dose) Table 178. North America Anthrax Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 179. North America Anthrax Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 180. North America Anthrax Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 181. North America Anthrax Vaccines Sales by Country (2021 VS 2025 VS 2032) & (M Doses) Table 182. North America Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 183. North America Anthrax Vaccines Sales by Country (2027-2032) & (M Doses) Table 184. North America Anthrax Vaccines Sales Price by Country (2021-2026) & (USD/Dose) Table 185. North America Anthrax Vaccines Sales Price by Country (2027-2032) & (USD/Dose) Table 186. United States Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 187. Canada Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 188. Mexico Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 189. Europe Anthrax Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 190. Europe Anthrax Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 191. Europe Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 192. Europe Anthrax Vaccines Sales by Type (2027-2032) & (M Doses) Table 193. Europe Anthrax Vaccines Sales Price by Type (2021-2026) & (USD/Dose) Table 194. Europe Anthrax Vaccines Sales Price by Type (2027-2032) & (USD/Dose) Table 195. Europe Anthrax Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 196. Europe Anthrax Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 197. Europe Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 198. Europe Anthrax Vaccines Sales by Application (2027-2032) & (M Doses) Table 199. Europe Anthrax Vaccines Sales Price by Application (2021-2026) & (USD/Dose) Table 200. Europe Anthrax Vaccines Sales Price by Application (2027-2032) & (USD/Dose) Table 201. Europe Anthrax Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. Europe Anthrax Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. Europe Anthrax Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. Europe Anthrax Vaccines Sales by Country (2021 VS 2025 VS 2032) & (M Doses) Table 205. Europe Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 206. Europe Anthrax Vaccines Sales by Country (2027-2032) & (M Doses) Table 207. Europe Anthrax Vaccines Sales Price by Country (2021-2026) & (USD/Dose) Table 208. Europe Anthrax Vaccines Sales Price by Country (2027-2032) & (USD/Dose) Table 209. Germany Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 210. France Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 211. U.K. Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 212. Italy Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 213. Russia Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 214. Spain Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 215. Netherlands Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 216. Switzerland Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 217. Sweden Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 218. Poland Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 219. China Anthrax Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 220. China Anthrax Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 221. China Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 222. China Anthrax Vaccines Sales by Type (2027-2032) & (M Doses) Table 223. China Anthrax Vaccines Sales Price by Type (2021-2026) & (USD/Dose) Table 224. China Anthrax Vaccines Sales Price by Type (2027-2032) & (USD/Dose) Table 225. China Anthrax Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 226. China Anthrax Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 227. China Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 228. China Anthrax Vaccines Sales by Application (2027-2032) & (M Doses) Table 229. China Anthrax Vaccines Sales Price by Application (2021-2026) & (USD/Dose) Table 230. China Anthrax Vaccines Sales Price by Application (2027-2032) & (USD/Dose) Table 231. Asia Anthrax Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 232. Asia Anthrax Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 233. Asia Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 234. Asia Anthrax Vaccines Sales by Type (2027-2032) & (M Doses) Table 235. Asia Anthrax Vaccines Sales Price by Type (2021-2026) & (USD/Dose) Table 236. Asia Anthrax Vaccines Sales Price by Type (2027-2032) & (USD/Dose) Table 237. Asia Anthrax Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 238. Asia Anthrax Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 239. Asia Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 240. Asia Anthrax Vaccines Sales by Application (2027-2032) & (M Doses) Table 241. Asia Anthrax Vaccines Sales Price by Application (2021-2026) & (USD/Dose) Table 242. Asia Anthrax Vaccines Sales Price by Application (2027-2032) & (USD/Dose) Table 243. Asia Anthrax Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 244. Asia Anthrax Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 245. Asia Anthrax Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 246. Asia Anthrax Vaccines Sales by Country (2021 VS 2025 VS 2032) & (M Doses) Table 247. Asia Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 248. Asia Anthrax Vaccines Sales by Country (2027-2032) & (M Doses) Table 249. Asia Anthrax Vaccines Sales Price by Country (2021-2026) & (USD/Dose) Table 250. Asia Anthrax Vaccines Sales Price by Country (2027-2032) & (USD/Dose) Table 251. Japan Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 252. South Korea Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 253. India Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 254. Australia Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 255. Taiwan Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 256. Southeast Asia Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 257. SAMEA Anthrax Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 258. SAMEA Anthrax Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 259. SAMEA Anthrax Vaccines Sales by Type (2021-2026) & (M Doses) Table 260. SAMEA Anthrax Vaccines Sales by Type (2027-2032) & (M Doses) Table 261. SAMEA Anthrax Vaccines Sales Price by Type (2021-2026) & (USD/Dose) Table 262. SAMEA Anthrax Vaccines Sales Price by Type (2027-2032) & (USD/Dose) Table 263. SAMEA Anthrax Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 264. SAMEA Anthrax Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 265. SAMEA Anthrax Vaccines Sales by Application (2021-2026) & (M Doses) Table 266. SAMEA Anthrax Vaccines Sales by Application (2027-2032) & (M Doses) Table 267. SAMEA Anthrax Vaccines Sales Price by Application (2021-2026) & (USD/Dose) Table 268. SAMEA Anthrax Vaccines Sales Price by Application (2027-2032) & (USD/Dose) Table 269. SAMEA Anthrax Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 270. SAMEA Anthrax Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 271. SAMEA Anthrax Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 272. SAMEA Anthrax Vaccines Sales by Country (2021 VS 2025 VS 2032) & (M Doses) Table 273. SAMEA Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 274. SAMEA Anthrax Vaccines Sales by Country (2027-2032) & (M Doses) Table 275. SAMEA Anthrax Vaccines Sales Price by Country (2021-2026) & (USD/Dose) Table 276. SAMEA Anthrax Vaccines Sales Price by Country (2027-2032) & (USD/Dose) Table 277. Brazil Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 278. Argentina Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 279. Chile Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 280. Colombia Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 281. Peru Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 282. Saudi Arabia Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 283. Israel Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 284. UAE Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 285. Turkey Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 286. Iran Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 287. Egypt Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Table 288. Key Raw Materials Table 289. Raw Materials Key Suppliers Table 290. Anthrax Vaccines Distributors List Table 291. Anthrax Vaccines Customers List Table 292. Research Programs/Design for This Report Table 293. Authors List of This Report Table 294. Secondary Sources Table 295. Primary Sources List of Figures Figure 1. Anthrax Vaccines Image Figure 2. Global Anthrax Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anthrax Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Live Vaccines Image Figure 5. Cell free PA Vaccines Image Figure 6. Global Anthrax Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Anthrax Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 8. Human Use Image Figure 9. Animal Use Image Figure 10. Global Anthrax Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Anthrax Vaccines Revenue (2021-2032) & (US$ Million) Figure 12. Global Anthrax Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Anthrax Vaccines Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Anthrax Vaccines Revenue Market Share by Region (2021-2032) Figure 15. Global Anthrax Vaccines Sales (2021-2032) & (M Doses) Figure 16. Global Anthrax Vaccines Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 17. Global Anthrax Vaccines Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Anthrax Vaccines Sales YoY (2021-2032) & (M Doses) Figure 19. Europe Anthrax Vaccines Sales YoY (2021-2032) & (M Doses) Figure 20. China Anthrax Vaccines Sales YoY (2021-2032) & (M Doses) Figure 21. Asia (Excluding China) Anthrax Vaccines Sales YoY (2021-2032) & (M Doses) Figure 22. South America, Middle East and Africa Anthrax Vaccines Sales YoY (2021-2032) & (M Doses) Figure 23. Global Anthrax Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Anthrax Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Anthrax Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Anthrax Vaccines Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Anthrax Vaccines Revenue Market Share by Type (2021-2032) Figure 29. Global Anthrax Vaccines Sales by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 30. Global Anthrax Vaccines Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Anthrax Vaccines Sales Market Share by Type (2021-2032) Figure 32. Global Anthrax Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Anthrax Vaccines Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Anthrax Vaccines Revenue Market Share by Application (2021-2032) Figure 35. Global Anthrax Vaccines Sales by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 36. Global Anthrax Vaccines Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Anthrax Vaccines Sales Market Share by Application (2021-2032) Figure 38. North America Anthrax Vaccines Revenue Share by Type (2021-2032) Figure 39. North America Anthrax Vaccines Sales Share by Type (2021-2032) Figure 40. North America Anthrax Vaccines Revenue Share by Application (2021-2032) Figure 41. North America Anthrax Vaccines Sales Share by Application (2021-2032) Figure 42. North America Anthrax Vaccines Revenue Share by Country (2021-2032) Figure 43. North America Anthrax Vaccines Sales Share by Country (2021-2032) Figure 44. Europe Anthrax Vaccines Revenue Share by Type (2021-2032) Figure 45. Europe Anthrax Vaccines Sales Share by Type (2021-2032) Figure 46. Europe Anthrax Vaccines Revenue Share by Application (2021-2032) Figure 47. Europe Anthrax Vaccines Sales Share by Application (2021-2032) Figure 48. Europe Anthrax Vaccines Revenue Share by Country (2021-2032) Figure 49. Europe Anthrax Vaccines Sales Share by Country (2021-2032) Figure 50. China Anthrax Vaccines Revenue Share by Type (2021-2032) Figure 51. China Anthrax Vaccines Sales Share by Type (2021-2032) Figure 52. China Anthrax Vaccines Revenue Share by Application (2021-2032) Figure 53. China Anthrax Vaccines Sales Share by Application (2021-2032) Figure 54. Asia Anthrax Vaccines Revenue Share by Type (2021-2032) Figure 55. Asia Anthrax Vaccines Sales Share by Type (2021-2032) Figure 56. Asia Anthrax Vaccines Revenue Share by Application (2021-2032) Figure 57. Asia Anthrax Vaccines Sales Share by Application (2021-2032) Figure 58. Asia Anthrax Vaccines Revenue Share by Country (2021-2032) Figure 59. Asia Anthrax Vaccines Sales Share by Country (2021-2032) Figure 60. SAMEA Anthrax Vaccines Revenue Share by Type (2021-2032) Figure 61. SAMEA Anthrax Vaccines Sales Share by Type (2021-2032) Figure 62. SAMEA Anthrax Vaccines Revenue Share by Application (2021-2032) Figure 63. SAMEA Anthrax Vaccines Sales Share by Application (2021-2032) Figure 64. SAMEA Anthrax Vaccines Revenue Share by Country (2021-2032) Figure 65. SAMEA Anthrax Vaccines Sales Share by Country (2021-2032) Figure 66. Anthrax Vaccines Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Anthrax Vaccines Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Live Vaccines
  • Cell free PA Vaccines
Applications
  • Human Use
  • Animal Use
Companies covered
  • Emergent BioSolutions
  • Merial
  • Merck
  • Zoetis
  • Bayer Sanidad Animal
  • Colorado Serum
  • PharmAthene
  • Tiankang
  • Biogénesis-Bago
  • CAVAC
  • Rosenbusch
  • Agrovet
  • Vecol
  • CVCRI
  • IVPM
  • Prondil
  • CDV
  • Indian Immunologicals
  • Botswana Vaccine Institute
  • Ceva Santé Animale
  • Intervac
  • JOVAC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anthrax Vaccines Market by Type
  3. 1.2.1 Global Anthrax Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Live Vaccines
  5. 1.2.3 Cell free PA Vaccines
  6. 1.3 Anthrax Vaccines Market by Application
  7. 1.3.1 Global Anthrax Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Human Use
  9. 1.3.3 Animal Use
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Anthrax Vaccines Market Dynamics
  1. 2.1 Anthrax Vaccines Industry Trends
  2. 2.2 Anthrax Vaccines Industry Drivers
  3. 2.3 Anthrax Vaccines Industry Opportunities and Challenges
  4. 2.4 Anthrax Vaccines Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Anthrax Vaccines Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Anthrax Vaccines Revenue by Region
  3. 3.2.1 Global Anthrax Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anthrax Vaccines Revenue by Region (2021-2026)
  5. 3.2.3 Global Anthrax Vaccines Revenue by Region (2027-2032)
  6. 3.2.4 Global Anthrax Vaccines Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Anthrax Vaccines Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Anthrax Vaccines Sales by Region
  9. 3.4.1 Global Anthrax Vaccines Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Anthrax Vaccines Sales by Region (2021-2026)
  11. 3.4.3 Global Anthrax Vaccines Sales by Region (2027-2032)
  12. 3.4.4 Global Anthrax Vaccines Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Anthrax Vaccines Revenue by Manufacturers
  2. 4.1.1 Global Anthrax Vaccines Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Anthrax Vaccines Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Anthrax Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anthrax Vaccines Sales by Manufacturers
  6. 4.2.1 Global Anthrax Vaccines Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Anthrax Vaccines Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Anthrax Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Anthrax Vaccines Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Anthrax Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Anthrax Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Anthrax Vaccines Manufacturers, Product Type & Application
  13. 4.7 Global Anthrax Vaccines Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Anthrax Vaccines Market CR5 and HHI
  16. 4.8.2 2025 Anthrax Vaccines Tier 1, Tier 2, and Tier 3
5 Anthrax Vaccines Market by Type
  1. 5.1 Global Anthrax Vaccines Revenue by Type
  2. 5.1.1 Global Anthrax Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Anthrax Vaccines Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Anthrax Vaccines Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Anthrax Vaccines Sales by Type
  6. 5.2.1 Global Anthrax Vaccines Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anthrax Vaccines Sales by Type (2021-2032) & (M Doses)
  8. 5.2.3 Global Anthrax Vaccines Sales Market Share by Type (2021-2032)
  9. 5.3 Global Anthrax Vaccines Price by Type
6 Anthrax Vaccines Market by Application
  1. 6.1 Global Anthrax Vaccines Revenue by Application
  2. 6.1.1 Global Anthrax Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Anthrax Vaccines Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Anthrax Vaccines Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Anthrax Vaccines Sales by Application
  6. 6.2.1 Global Anthrax Vaccines Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Anthrax Vaccines Sales by Application (2021-2032) & (M Doses)
  8. 6.2.3 Global Anthrax Vaccines Sales Market Share by Application (2021-2032)
  9. 6.3 Global Anthrax Vaccines Price by Application
7 Company Profiles
  1. 7.1 Emergent BioSolutions
  2. 7.1.1 Emergent BioSolutions Company Information
  3. 7.1.2 Emergent BioSolutions Business Overview
  4. 7.1.3 Emergent BioSolutions Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Emergent BioSolutions Anthrax Vaccines Product Portfolio
  6. 7.1.5 Emergent BioSolutions Recent Developments
  7. 7.2 Merial
  8. 7.2.1 Merial Company Information
  9. 7.2.2 Merial Business Overview
  10. 7.2.3 Merial Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Merial Anthrax Vaccines Product Portfolio
  12. 7.2.5 Merial Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck Anthrax Vaccines Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Zoetis
  20. 7.4.1 Zoetis Company Information
  21. 7.4.2 Zoetis Business Overview
  22. 7.4.3 Zoetis Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Zoetis Anthrax Vaccines Product Portfolio
  24. 7.4.5 Zoetis Recent Developments
  25. 7.5 Bayer Sanidad Animal
  26. 7.5.1 Bayer Sanidad Animal Company Information
  27. 7.5.2 Bayer Sanidad Animal Business Overview
  28. 7.5.3 Bayer Sanidad Animal Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Bayer Sanidad Animal Anthrax Vaccines Product Portfolio
  30. 7.5.5 Bayer Sanidad Animal Recent Developments
  31. 7.6 Colorado Serum
  32. 7.6.1 Colorado Serum Company Information
  33. 7.6.2 Colorado Serum Business Overview
  34. 7.6.3 Colorado Serum Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Colorado Serum Anthrax Vaccines Product Portfolio
  36. 7.6.5 Colorado Serum Recent Developments
  37. 7.7 PharmAthene
  38. 7.7.1 PharmAthene Company Information
  39. 7.7.2 PharmAthene Business Overview
  40. 7.7.3 PharmAthene Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 PharmAthene Anthrax Vaccines Product Portfolio
  42. 7.7.5 PharmAthene Recent Developments
  43. 7.8 Tiankang
  44. 7.8.1 Tiankang Company Information
  45. 7.8.2 Tiankang Business Overview
  46. 7.8.3 Tiankang Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Tiankang Anthrax Vaccines Product Portfolio
  48. 7.8.5 Tiankang Recent Developments
  49. 7.9 Biogénesis-Bago
  50. 7.9.1 Biogénesis-Bago Company Information
  51. 7.9.2 Biogénesis-Bago Business Overview
  52. 7.9.3 Biogénesis-Bago Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Biogénesis-Bago Anthrax Vaccines Product Portfolio
  54. 7.9.5 Biogénesis-Bago Recent Developments
  55. 7.10 CAVAC
  56. 7.10.1 CAVAC Company Information
  57. 7.10.2 CAVAC Business Overview
  58. 7.10.3 CAVAC Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 CAVAC Anthrax Vaccines Product Portfolio
  60. 7.10.5 CAVAC Recent Developments
  61. 7.11 Rosenbusch
  62. 7.11.1 Rosenbusch Company Information
  63. 7.11.2 Rosenbusch Business Overview
  64. 7.11.3 Rosenbusch Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Rosenbusch Anthrax Vaccines Product Portfolio
  66. 7.11.5 Rosenbusch Recent Developments
  67. 7.12 Agrovet
  68. 7.12.1 Agrovet Company Information
  69. 7.12.2 Agrovet Business Overview
  70. 7.12.3 Agrovet Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Agrovet Anthrax Vaccines Product Portfolio
  72. 7.12.5 Agrovet Recent Developments
  73. 7.13 Vecol
  74. 7.13.1 Vecol Company Information
  75. 7.13.2 Vecol Business Overview
  76. 7.13.3 Vecol Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Vecol Anthrax Vaccines Product Portfolio
  78. 7.13.5 Vecol Recent Developments
  79. 7.14 CVCRI
  80. 7.14.1 CVCRI Company Information
  81. 7.14.2 CVCRI Business Overview
  82. 7.14.3 CVCRI Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 CVCRI Anthrax Vaccines Product Portfolio
  84. 7.14.5 CVCRI Recent Developments
  85. 7.15 IVPM
  86. 7.15.1 IVPM Company Information
  87. 7.15.2 IVPM Business Overview
  88. 7.15.3 IVPM Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 IVPM Anthrax Vaccines Product Portfolio
  90. 7.15.5 IVPM Recent Developments
  91. 7.16 Prondil
  92. 7.16.1 Prondil Company Information
  93. 7.16.2 Prondil Business Overview
  94. 7.16.3 Prondil Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Prondil Anthrax Vaccines Product Portfolio
  96. 7.16.5 Prondil Recent Developments
  97. 7.17 CDV
  98. 7.17.1 CDV Company Information
  99. 7.17.2 CDV Business Overview
  100. 7.17.3 CDV Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 CDV Anthrax Vaccines Product Portfolio
  102. 7.17.5 CDV Recent Developments
  103. 7.18 Indian Immunologicals
  104. 7.18.1 Indian Immunologicals Company Information
  105. 7.18.2 Indian Immunologicals Business Overview
  106. 7.18.3 Indian Immunologicals Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Indian Immunologicals Anthrax Vaccines Product Portfolio
  108. 7.18.5 Indian Immunologicals Recent Developments
  109. 7.19 Botswana Vaccine Institute
  110. 7.19.1 Botswana Vaccine Institute Company Information
  111. 7.19.2 Botswana Vaccine Institute Business Overview
  112. 7.19.3 Botswana Vaccine Institute Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Botswana Vaccine Institute Anthrax Vaccines Product Portfolio
  114. 7.19.5 Botswana Vaccine Institute Recent Developments
  115. 7.20 Ceva Santé Animale
  116. 7.20.1 Ceva Santé Animale Company Information
  117. 7.20.2 Ceva Santé Animale Business Overview
  118. 7.20.3 Ceva Santé Animale Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Ceva Santé Animale Anthrax Vaccines Product Portfolio
  120. 7.20.5 Ceva Santé Animale Recent Developments
  121. 7.21 Intervac
  122. 7.21.1 Intervac Company Information
  123. 7.21.2 Intervac Business Overview
  124. 7.21.3 Intervac Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Intervac Anthrax Vaccines Product Portfolio
  126. 7.21.5 Intervac Recent Developments
  127. 7.22 JOVAC
  128. 7.22.1 JOVAC Company Information
  129. 7.22.2 JOVAC Business Overview
  130. 7.22.3 JOVAC Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 JOVAC Anthrax Vaccines Product Portfolio
  132. 7.22.5 JOVAC Recent Developments
8 North America
  1. 8.1 North America Anthrax Vaccines Market Size by Type
  2. 8.1.1 North America Anthrax Vaccines Revenue by Type (2021-2032)
  3. 8.1.2 North America Anthrax Vaccines Sales by Type (2021-2032)
  4. 8.1.3 North America Anthrax Vaccines Price by Type (2021-2032)
  5. 8.2 North America Anthrax Vaccines Market Size by Application
  6. 8.2.1 North America Anthrax Vaccines Revenue by Application (2021-2032)
  7. 8.2.2 North America Anthrax Vaccines Sales by Application (2021-2032)
  8. 8.2.3 North America Anthrax Vaccines Price by Application (2021-2032)
  9. 8.3 North America Anthrax Vaccines Market Size by Country
  10. 8.3.1 North America Anthrax Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Anthrax Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Anthrax Vaccines Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Anthrax Vaccines Market Size by Type
  2. 9.1.1 Europe Anthrax Vaccines Revenue by Type (2021-2032)
  3. 9.1.2 Europe Anthrax Vaccines Sales by Type (2021-2032)
  4. 9.1.3 Europe Anthrax Vaccines Price by Type (2021-2032)
  5. 9.2 Europe Anthrax Vaccines Market Size by Application
  6. 9.2.1 Europe Anthrax Vaccines Revenue by Application (2021-2032)
  7. 9.2.2 Europe Anthrax Vaccines Sales by Application (2021-2032)
  8. 9.2.3 Europe Anthrax Vaccines Price by Application (2021-2032)
  9. 9.3 Europe Anthrax Vaccines Market Size by Country
  10. 9.3.1 Europe Anthrax Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Anthrax Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Anthrax Vaccines Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Anthrax Vaccines Market Size by Type
  2. 10.1.1 China Anthrax Vaccines Revenue by Type (2021-2032)
  3. 10.1.2 China Anthrax Vaccines Sales by Type (2021-2032)
  4. 10.1.3 China Anthrax Vaccines Price by Type (2021-2032)
  5. 10.2 China Anthrax Vaccines Market Size by Application
  6. 10.2.1 China Anthrax Vaccines Revenue by Application (2021-2032)
  7. 10.2.2 China Anthrax Vaccines Sales by Application (2021-2032)
  8. 10.2.3 China Anthrax Vaccines Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anthrax Vaccines Market Size by Type
  2. 11.1.1 Asia Anthrax Vaccines Revenue by Type (2021-2032)
  3. 11.1.2 Asia Anthrax Vaccines Sales by Type (2021-2032)
  4. 11.1.3 Asia Anthrax Vaccines Price by Type (2021-2032)
  5. 11.2 Asia Anthrax Vaccines Market Size by Application
  6. 11.2.1 Asia Anthrax Vaccines Revenue by Application (2021-2032)
  7. 11.2.2 Asia Anthrax Vaccines Sales by Application (2021-2032)
  8. 11.2.3 Asia Anthrax Vaccines Price by Application (2021-2032)
  9. 11.3 Asia Anthrax Vaccines Market Size by Country
  10. 11.3.1 Asia Anthrax Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Anthrax Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Anthrax Vaccines Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anthrax Vaccines Market Size by Type
  2. 12.1.1 SAMEA Anthrax Vaccines Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Anthrax Vaccines Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Anthrax Vaccines Price by Type (2021-2032)
  5. 12.2 SAMEA Anthrax Vaccines Market Size by Application
  6. 12.2.1 SAMEA Anthrax Vaccines Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Anthrax Vaccines Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Anthrax Vaccines Price by Application (2021-2032)
  9. 12.3 SAMEA Anthrax Vaccines Market Size by Country
  10. 12.3.1 SAMEA Anthrax Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Anthrax Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Anthrax Vaccines Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Anthrax Vaccines Value Chain Analysis
  2. 13.1.1 Anthrax Vaccines Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Anthrax Vaccines Production Mode & Process
  6. 13.2 Anthrax Vaccines Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Anthrax Vaccines Distributors
  9. 13.2.3 Anthrax Vaccines Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst